Vericiguat

Verquvo (vericiguat) is a small molecule pharmaceutical. Vericiguat was first approved as Verquvo on 2021-01-19. It has been approved in Europe to treat heart failure. It is known to target guanylate cyclase soluble subunit alpha-1, guanylate cyclase soluble subunit alpha-2, and guanylate cyclase soluble subunit beta-1. Verquvo's patents are valid until 2032-11-26 (FDA).